BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27148755)

  • 1. Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.
    Harland AA; Bender AM; Griggs NW; Gao C; Anand JP; Pogozheva ID; Traynor JR; Jutkiewicz EM; Mosberg HI
    J Med Chem; 2016 May; 59(10):4985-98. PubMed ID: 27148755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
    Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
    J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
    J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
    Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.
    Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y
    Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
    Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
    Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
    Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
    J Med Chem; 2009 Dec; 52(23):7724-31. PubMed ID: 19788201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
    Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
    Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opiate antagonist prevents μ- and δ-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth.
    Sarkar DK; Sengupta A; Zhang C; Boyadjieva N; Murugan S
    J Biol Chem; 2012 May; 287(20):16734-47. PubMed ID: 22451667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
    Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
    Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
    Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
    Milan-Lobo L; Whistler JL
    J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore.
    Henry S; Anand JP; Brinkel AC; McMillan DM; Twarozynski JJ; Loo CE; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2021 Jan; 12(1):216-233. PubMed ID: 33346631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.
    Nastase AF; Anand JP; Bender AM; Montgomery D; Griggs NW; Fernandez TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2019 Apr; 62(8):4193-4203. PubMed ID: 30916966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mu-opioid receptor and delta-opioid receptor differentially regulate microglial inflammatory response to control proopiomelanocortin neuronal apoptosis in the hypothalamus: effects of neonatal alcohol.
    Shrivastava P; Cabrera MA; Chastain LG; Boyadjieva NI; Jabbar S; Franklin T; Sarkar DK
    J Neuroinflammation; 2017 Apr; 14(1):83. PubMed ID: 28407740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
    Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
    J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.